logo
Twitter
Discord
Email
logo
Option Care Health, Inc.

Option Care Health, Inc.

NASDAQ•OPCH
CEO: Mr. John C. Rademacher
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 1996-08-15
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Contact Information
3000 Lakeside Drive, Suite 300N, Bannockburn, IL, 60015, United States
312-940-2443
www.optioncarehealth.com
Market Cap
$5.85B
P/E (TTM)
28.1
29.3
Dividend Yield
--
52W High
$36.32
52W Low
$24.24
52W Range
98%
Rank44Top 53.8%
3.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$1.44B+12.24%
4-Quarter Trend

EPS

$0.32+0.00%
4-Quarter Trend

FCF

$157.90M+4.76%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Net Revenue Increased 12.2% Net Revenue for Q3 2025 reached $1.44B USD, marking a 12.2% increase over Q3 2024 results driven by organic growth.
Gross Profit Rises Moderately Q3 Gross Profit increased by $16.2M USD to $272.9M USD, reflecting growth in revenue and therapy mix compared to prior year.
Intramed Plus Acquisition Closed Acquired Intramed Plus for $117.2M USD net cash, adding $66.4M USD in goodwill during the nine months period.
Strong Stock Repurchase Activity Company spent $212.5M USD on share repurchases in nine months; $287.5M USD remains authorized for future buybacks.

Risk Factors

Gross Margin Compression Noted Q3 Gross Margin fell to 19.0% from 20.1% due to certain higher cost therapies included within chronic growth segments.
Operating Cash Flow Decreased Nine Months Cash from Operations dropped $64.7M USD to $222.6M USD, impacted by working capital usage and inventory increases.
Debt Refinancing Impact Recognized Debt refinancing incurred a $4.7M USD loss on extinguishment and $6.7M USD in issuance costs during the quarter.
Supplier Concentration Exists 66% to 67% of pharmaceutical and supply purchases rely on just four vendors, posing potential service delivery delays risk.

Outlook

Liquidity Position Remains Stable Existing cash balances and expected operating cash flows are believed sufficient to meet operating requirements over the next 12 months.
Debt Structure Optimized Post-Refinance Fourth Amendment reduced First Lien Term Loan rate and extended maturity to September 22, 2032, enhancing terms.
Acquisitions Remain Key Strategy Company continues to evaluate acquisition opportunities as a key part of growth strategy, potentially requiring additional capital.
Interest Rate Hedge Active Interest rate cap hedge remains active for five years, partially offsetting risk associated with the First Lien Term Loan variable rate.

Peer Comparison

Revenue (TTM)

Option Care Health, Inc.OPCH
$5.53B
+15.8%
Chemed CorporationCHE
$2.53B
+6.5%
Lantheus Holdings, Inc.LNTH
$1.53B
+1.9%

Gross Margin (Latest Quarter)

NewAmsterdam Pharma Company N.V.NAMS
100.0%
+0.0pp
Crinetics Pharmaceuticals, Inc.CRNX
100.0%
+0.0pp
Lantheus Holdings, Inc.LNTH
57.9%
-6.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CHE$6.58B23.624.4%8.7%
OPCH$5.85B28.115.3%36.7%
CRNX$5.74B-12.5-35.1%4.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.1%
Moderate Growth
4Q Net Income CAGR
-4.8%
Stable Profitability
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Next earnings:Feb 25, 2026
|
EPS:$0.46
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 30, 2025|
    Revenue: $1.44B+12.2%
    |
    EPS: $0.32+0.0%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 30, 2025|
    Revenue: $1.42B+15.4%
    |
    EPS: $0.31+0.0%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: Apr 29, 2025|
    Revenue: $1.33B+16.3%
    |
    EPS: $0.28+7.7%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 26, 2025|
    Revenue: $5.00B+16.2%
    |
    EPS: $1.23-17.4%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 30, 2024|
    Revenue: $1.28B+17.0%
    |
    EPS: $0.32+3.2%
    Beat
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 31, 2024|
    Revenue: $1.23B+14.8%
    |
    EPS: $0.31-51.6%
    Beat
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: Apr 23, 2024|
    Revenue: $1.15B+12.8%
    |
    EPS: $0.26+18.2%
    Beat
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 22, 2024|
    Revenue: $4.30B+9.1%
    |
    EPS: $1.49+79.5%
    Beat